

CENTER FOR GLOBAL CLINICAL RESEARCH DATA

Vivli Clinical Research Data Sharing: Share. Discover. Innovate.

May 16, 2019
Johns Hopkins Medical School
Rebecca Li, PhD, Executive Director

Agenda

- Why share data?
- Sharing participant-level data using the Vivli Platform
- What are the requirements today? By journals and funders
- How can I benefit from using data in the Vivli platform ?
- Q&A



Data Sharing in the News



CLINICAL TRIALS

Science

A new portal for patient data

Vivli aims to ease sharing of anonymized clinical studies

By Joselyn Kalser

nder pressure to be more transquarent about the sessils of drug testing studies, some companies have begun to share an oxymsted patient data from clinical trials with approved researchers on secure websites. An online platform launched this week aims to espand such afforts by offering a one-stop dearing-house for those seeking to mise these data for new insplict.

The platform, created by Vivii, a nonprofit based in Cambridge, Massachusetts, debuts with access to more than 4000 clinicall rial data sets from eight companies and morprofits. It also features tools for combin-

ing and analyzing the data.
"This is the first time it's all going to be available in one place," Vivil Executive Direc-

tor Rebecca IJ says.
Vidt, which span out of a
policy think tank at Harvard
University-affiliated Brigham
and Women's Hospital in
Roston, is part of a push to
encourage drug developes to

share trial data—even negative results, findlegs that show a teatment has no benefit. Companies seeking US: regulatory approval for a drug, as well as investigators funded by the National Buttures of Health, must post limited, summ any results on Clinical-Pikalagor. Sut many researchers and policy analysts believe sharing detailed raw data on information, would be valuable. Researchers could confirm that a drug works, look for side effects, or exporte new questions.

Starting this mooth, the International Committee of Modical Journal Editors—which includes the leaders of many major journals—will aik submitting authors to include a data sharing plan that can include patient data. Such sharing semains controversial. In 2016, Jeffrey Irann, editor of the New England Journal of Medicine, worried in an aditorial that it would embedien 'resuch peassive'—ederities who request others' data and quickly publish papers, years preempting the actentials who generated the data. But Drazen utilizately endorsed the committee by plan.

Some companies have already responded.

Drug giant Johnson & Johnson allows

researchers to request patient data at a 5-year-old site osiled YCDA, spomsored by Yale University, whemas GlaxoSmithEline and 35 other firms share data at Clinics-StudyDataRequest.com.

Vivil same to extreamiline research erri ability to find, request, and combine data from these and other sites, Li says. It will both list data deposited elsewhere and eventually host data sets. Cli sodewhere and eventually host data sets. Cli sodewhere in the set of the country list of the set of the country list of the cou

Companies can purchase

share their data. Academic sessachers will pay \$2000 to \$4500 per study for stor-

age and sharing services.

"This is the first time it's all going to be available in one place."

e place." Data miners can beely use the siteth basic tools for a year, but after that will pay a daily se of \$12.0 toth the \$30 daily for place of \$12.0 toth the \$30 daily for place of \$12.0 toth the \$30 daily for place of \$12.0 toth the \$30 daily

help remarchers cover data submission costs. At the Gates Fou ndation in Seatife, Westhelpfor, officials antideate that many grantess will deposit their clinical trial results in Vivil in order to meet the foundation's datasharing requirements. And Harvard officials will be encouraging faculty to add their discal data sets, including hundreds from alneady completed studies.

Some data sharing advocates are pleased by Writs arrival. We need to get every one behind one platform instead of rhaone behind one platform instead of rhaning a proliferation of these things," says epidemiologist Evan May-Wilson of Johnson Hop ins University in Baltimore, Maryland. There is uncertainty about demand, however. A 2016 study by researchers at Duke University in Durham, North Carolina, found that sole sit is had sequented access to just 16% of more than 2000 patient data sets available on three platforms. One obstacle was the difficulty finding the data, says Duke cardiologist Eric Peterson, an author. Vivil could sesoive that p solbem, be says, by serving as a clinical data "cust castlog."

With reporting by Elizabeth Gamillo.

sciencemag.org SCIENCE



Why should I share my data?

- Journal and funder mandates
- Increase citations
- Moral obligations (owe it to trial participants)



Evolution of Transparency in Clinical Trial Data

Raw data (IPD) shared

Summary data shared

FDAAA Final Rule (2016) EU no. 536/2014 requires lay summaries EMA Policy 0070 (2014), Policy 0043 (TBD)

PhRMA/EFPIA principles for data sharing (2014)

IOM Sharing Clinical Trial Data report (2015)

ICMJE IPD sharing statement (July 2018)

Clinical trials registration

ICMJE requirement for publication (2004) FDAAA requirement for applicable trials (2007)



Why should I share my data?

- Journal and funder mandates
- Increase citations
- Moral obligations (owe it to trial participants)



Rewards and recognition for sharing

 Studies that made data available in a public repository received 9% more citations than similar studies that did not



- Sharing facilitates science
- Data availability was associated with a citation benefit and the number of reuse papers grows rapidly over years

Piwowar, Heather A., and Todd J. Vision. "Data reuse and the open data citation advantage." *PeerJ* 1 (2013): e175.



Why Should I Share my Data?


Journal and funder mandates

Increase citations

Moral obligations (owe it to trial participants)



Patients demand data sharing and reuse



Barriers to IPD Sharing for Academics

For most academic trialists (Data Contributors)

- secure data hosting and sharing platforms not available or limited to within the institution
- no standard data use and data sharing agreements
- no independent review process available to adjudicate data requests
- cost and difficulty of de-identifying IPD and making it available
- All this makes it difficult to meet data sharing requirements

For Data Users

- difficult to discover what IPD is available for sharing
- combining datasets from different platforms is resource- and time-intensive
- different data standards, data requirements, security standards, policies
- disease-specific data sharing platforms limit cross-disciplinary data discovery
- limited range of analytic tools available



Vivli Addresses Pain Points for Contributors and Requesters

	IPD Sharing Requirements	Figshare	Dryad	CT.gov	Vivli
Data Contributors	IPD can be stored and securely hosted				
	Harmonized data contributor and data use agreements				
	IPD can be shared securely to anyone in the world				
	Independent review available				

Introducing Vivli

THE ENTITY

- Non-profit organization
- Convening function
 - Biomedical industry (pharma, bio, device)
 - Academia
 - Non-profit funders and foundations
 - Government (funders and regulators)
 - Patient/patient advocates
- Governance and policy
 - Harmonizing language & agreements
 - Move culture of data sharing
- Advocacy
 - Lowering barriers
 - Promoting incentives
- Oversight of Implementation

THE PLATFORM

- A user-friendly, secure, state-of-the art data sharing and computing platform
- Serving the international community, including trials from any disease, country, sponsor, funder, or investigator
 - Open search
 - Robust security
 - Modern tools and technologies

Vivli By the Numbers



abbvie

Aegerion® Pharmaceuticals ANOVELION THERAPEUTICS COMPANY









Vivli Members













HARVARD

UNIVERSITY













Founding Funders and Partners

ROPES&GRAY















For Grant Submission

Funders increasingly requiring data sharing

Draft NIH Data Sharing and Management Policy is requiring

- IPD sharing plan for all grants
- sharing and managing of data according to approved plan

Vivli provides an NIH-compliant data sharing plan <u>template</u>

Data sharing costs should be part of the budget proposal

https://vivli.org/resources/resources/



Vivli Template Data Sharing Plan

As part of our ongoing efforts to support the broader research community, Vivil has provided the following template language for a data management plan, based on Nill requirements. The Nill sucrets, "Applicants who are planning to share data may wish to describe briefly the expected schedule for data sharing, the format of the final dataset, the documentation to be provided, whether or not any analytic tools also will be provided, whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement [including the criteria for deciding who can receive the data and whether or not any conditions will be placed on their use], and the mode of data sharing [e.g., under their own auspices by mailing a disk or posting data on their institutional or personal website, through a data archive or enclave]. Investigators choosing to share under their own auspices may wish to enter into a data-sharing agreement."

Template:

The proposed research will include data from approximately (number of participants) participants recruited from clinical facilities in the (location) area with (population being studied; i.e. T2 disbetes). The final dataset will include (data included such as self-reported demographic and behavioral data from interviews with participants, and isboratory data from stood and urine specimens provided). We will share individual-participant level or IPD data. The data will be made available 1 year after completion of the study, in a de-identified format. In addition to the IPD data set, the researcher will share the (elements of the final data set and documentation to be shared, i.e. data set, data dictionary, statistical analysis plan, analytic code, and final protocol with amendments.)

Vivil will then make the data available, without cost, to users. Vivil will maintain storage and access of the data for as long as it maintains scientific utility. Costs for sharing this project's data through Vivil are included in the proposed budget.

:

Journal Mandates as of July 1, 2018

The NEW ENGLAND JOURNAL of MEDICINE

EDITORIALS



Data Sharing Statements for Clinical Trials — A Requirement of the International Committee of Medical Journal Editors

The International Committee of Medical Journal explained at www.icmje.org/recommendations/

Editors (ICMJE) believes there is an ethical oblibrowse/publishing-and-editorial-issues/clinical gation to responsibly share data generated by -trial-registration.html. If the data sharing plan

Taichman DB, et al. N Engl J Med 2017; 376:2277-2279

- ICMIF includes
 - NEJM, JAMA, The Lancet, BMJ, Annals of Internal Med, PLoS Medicine, others
- Trial manuscripts must be submitted with a data sharing statement
 - how Individual participant-level data (IPD) will be shared - who, what, when, where, and why
- IPD sharing is not (yet) required but "editors may take into consideration data sharing statements when making editorial decisions"

At Trial Registration

- Data sharing plan is part of the ClinicalTrials.gov registration record
- Undecided is allowed in ClinicalTrials.gov but not by ICMJE
- As of <u>January 1, 2019</u>, ICMJE requires registration of your data sharing plan at time of trial registration
- This is a radical departure for most investigators to declare their sharing intentions upfront!

▼ 12. IPD Sharing Statement

Plan to Share IPD

Definition: Indicate whether there is a plan to make individual participant data (IPD) collected in this study, including data dictionaries, available to other researchers (typically after the end of the study). Select one.

- Yes: There is a plan to make IPD and related data dictionaries available.
- · No: There is not a plan to make IPD available.
- Undecided: It is not yet known if there will be a plan to make IPD available.

IPD Sharing Plan Description

Definition: If Plan to Share IPD is "Yes," briefly describe what specific individual participant data sets are to be shared (for example, all

http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html



Data Sharing Plan for ICMJE Journal Submission

ICMJE Question	If using Vivli, proposed response		
Will IPD (and data dictionaries) be made available?	Yes		
What data in particular will be shared?	Final cleaned individual participant-level data, de-identified		
What other documents will be made available?	Final protocol, statistical analysis plan, and the data dictionary. (Note: additional documents such as CRFs and analytic code may also be included.)		
When will data be made available?	X months /years after study completion		
With whom?	Anyone with the relevant skillsets to conduct the analysis and has submitted an approved proposal on Vivli. Proposals are submitted on vivli.org .		
For what types of analysis?	To achieve the aims and objectives in the scientific proposal as approved via Vivli.		
By what mechanism will data be made available?	Following an approved request, a data use agreement must be signed. Data are made available via a secure research environment or download.		

At Trial Completion

- JHMI is an institutional member of Vivli
 - Your membership covers the costs to store and share your study
- To host/archive your study on Vivli
 - Send us your NCT ID (Clinicaltrial.gov identifier)
 - Provide IPD Data Package to Vivli
- Vivli takes care of long-term data sharing even after your grant funds end




Contents of the IPD Package*

Item	Description		
Required			
Study protocol	Final protocol with all amendments		
Informed consent form	Final approved informed consent form		
Data dictionary	Detailed descriptions of each variable in the dataset, including the definition, source, coding, etc. of the variable		
Statistical Analysis Plan	Description of the principal features of the analyses described in the protocol		
IPD dataset	Final cleaned individual participant-level data, de-identified		
Optional			
Analytic code	Software code used to carry out prespecified and additional analyses		
Case report forms	Forms used to collect the data that is described in the protocol for each trial participant		
Clinical Study Report (CSR)	Report that summarizes the efficacy and safety data from the study (after regulatory decision)		

NOTE: *this is a subset of the entire full data package and includes the data that underlies the publication findings (tables, figures)



Data Sharing Timeline Summarized



Providing IPD Data Package

DE-IDENTIFY DATA

Vivli accepts de-identified data from completed trials

Confirm data package elements for sharing (protocol, data dictionary, statistical analysis plan, and individual participant level data)

SIGN AGREEMENT

Contact support@vivli.org for the **Data Contribution Agreement**, which needs to be signed by the Principle Investigator.

Returned signed version.

PROVIDE YOUR DATA

Vivli will then provide access to its platform to upload your data. This is an easy drag and drop file-sharing process with support available every step of the way.

Data will be archived and a DOI assigned.





De-identification/Anonymization

IPD must be transformed to reduce the risk of re-identification of study participants

Vivli can connect you with our partner Privacy Analytics to deidentify/anonymize your data if necessary at a discount



Data Standardization Approach

IPD is recommended to be in CDISC <u>SDTM</u> format

No requirements for using standardized data variables or common data elements (CDEs)



When a Data Request is made

- Vivli manages the administration of data requests and makes the process easy for data contributors
- Approved requests are published on Vivli
 - title, lay summary, and name of requester
 - annual usage reports shared with your institution
- Under the Hopkins membership agreement, Hopkins IPD packages are downloadable by approved requesters



Why are DOIs important in data sharing?

- Digital Object Identifiers (DOIs) are persistent, citable and unique links on the internet. They help the community locate and cite data and objects.
- Vivli assigns a persistent identifier (DOI) to datasets and other objects (such as publications)
- DOIs facilitate subsequent attribution and data sharing
- They are 'minted' by several known entities




Repository & DOI updates

- All data shared on Vivli & approved data requests are provided a DOI minted by DataCite
- Vivli is presently listed on FAIR Sharing and by the BMJ
- Vivli is engaged in ongoing discussions to be added as a recommended repository for a number of journals and funders






DOI, study listed on Vivli



Sample DOI, approved data request



WVivli



- No cost Sharing de-identified data <u>covered</u>
 by membership in Vivli
- Citation DOIs allow for citation and credit of your research data
- Metrics Yearly metrics on number of data requests, resulting publications, etc.
- Long-term archiving Archive your trials on Vivli (at least 25 years)
- Post-grant data sharing IPD sharing solution that continues even after grant funds end
- Funder and journal mandates Use Vivli to easily fulfill data sharing plan mandates




CENTER FOR GLOBAL CLINICAL RESEARCH DATA

How to Access Data in Vivli?



1.9M
Participants from
100
countries

Data Request and Access Process



Short video demo at https://vivli.org/resources/vivli-platform-demo/



Secure Environment Bridges Multiple Platforms












Vivli Secure Environment





Data Contributors 🚑 Data Requesters


- Recognize value and opportunity -- but also burden -- of data contributors responding to data requesters and vice versa
 - communication and collaboration is entirely up to the parties involved
 - see Vivli <u>webinar</u> on how to prepare high quality data proposals
- Publications arising from use of Vivli data must
 - acknowledge use of the original data (by DOI citation)
 - be reported back to Vivli for tracking purposes



Summary: Benefits of Requesting Data through Vivli

- One-stop search find individual-level participant data from more than 3,200 completed clinical trials
- Harmonized request form use a single data request form for all studies
- Bridges platforms can bring together data sets from Vivli and multiple other platforms
- Secure yet customizable bring in your own data, tools and scripts to a secure research environment







Questions?



User fees

Environment Type	Compute Charge (for 2018-2019)	Size of Compute Space and Tools
Standard Research Environment	No charge, 365 days \$12/day after 365 days, 2 concurrent logins and unlimited users can have access to the platform	(2CPUx7GB) size Office 365, Jupyter notebook, Python, STATA and R tools available
Premium Research Environment	No charge, 90 days \$25/day after first 90 days, 2 concurrent logins and unlimited users can have access to the platform	(4CPUx14GB) size Office 365, Jupyter notebook, Python, R, STATA and SAS (academic license) tools are available

Cost of sharing a single academic study on Vivli

	Study Metadata Curated and Listed on Vivli	Anonymized IPD Storage	Independent Review Panel	One-time Cost
Study ready for sharing and needs storage	✓	✓		\$2,000*
Study ready for sharing and needs Storage and Independent Review Panel	✓	✓	√	\$4,500
Anonymization	✓	✓	✓	Provided by Privacy Analytics (additional \$2,000-\$5000 / dataset)

^{*}Anonymized data and documentation must be shared at the time of curating and listing the study and be available for download. Contributors must sign harmonized Data Contributor Agreement and Data Use Agreement.

Does not include being named as a member for the institution or attendance at the Vivli Steering Committee.